Laura-Sophie Landwehr

14PUBLICATIONS
51CO-AUTHORS
Molecular targetsNeurology and neuromuscular diseasesMacromolecular materialsPredictive and prognostic markersSolid tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 13, 2026
Pan-CDK and PLK1 inhibitors as a novel approach for targeted treatment of adrenocortical carcinomas.

|Aug 13, 2026
ELAVL1-KO Affects Steroid Synthesis in ACC Cell Line NCI-H295R and Reduces Colony-Forming Abilities.

|May 13, 2026
Impact of Neuroendocrine Neoplasm-Specific Systemic Treatments on Somatostatin Receptors Expression and Function in Neuroendocrine Tumor Cells.

|Sep 19, 2025
World first hybrid neuroendocrine cell line sharing properties of NET G3 and dedifferentiated NEC.

Dorothee Rogoll, Laura-Sophie Landwehr, Jochen Schreiner

|Jun 26, 2025
Mitotane treatment of adrenocortical carcinoma induces tumoural secretion of GDF-15: impact on poor prognosis and impaired responsiveness to immunotherapy.

Isabel Weigand, Alexandra S Triebig, Tanja Maier

|Aug 22, 2024
Primary unilateral macronodular adrenal hyperplasia with concomitant glucocorticoid and androgen excess and KDM1A inactivation.

Yasir S Elhassan, Silke Appenzeller, Laura-Sophie Landwehr

Pageof 3

Frequent Collaborators

8 joint publications

Martin Fassnacht

6 joint publications

Barbara Altieri

5 joint publications

Silviu Sbiera

5 joint publications

Cristina L Ronchi